Host sponsor
Our mission at the South East Health Technologies Alliance (SEHTA) is to facilitate the profitable and sustainable growth of companies in South East England's health technologies sector - biotechnology, diagnostics, medical devices and pharmaceuticals.
Funded primarily by the South East England Development Agency (SEEDA), one of the primary aims of SEHTA is to support the growth of mid-sized companies in the sector by providing access to business support, grants and finance advice, networking and collaboration opportunities.
SEHTA also acts as an intermediary, bridging the gap between our members and policymakers, regulators, the media and the general public in order to improve the environment in which our members operate. Through these relationships SEHTA creates alliances between key players in the health technologies community.
With a £6 billion share of a £120 billion global market, the health technology sector is one of the great hopes for the sustainability of the UK economy. With revenues of £58 billion generated from the health supply chain, the SEEDA region contributes extensively to the economic prosperity of the UK, supported by 22 universities and over 1000 health technology companies.
As a member you can drive the future direction of SEHTA to benefit you and your company.
If you would like further information please contact:
Haley Dwyer
Event and Bursary sponsor
Avecia Biologics is a leader in the process development and manufacture of biologics, offering proprietary expression
and gene manipulation systems for microbial- and mammalian-derived biopharmaceuticals, including its pAVEway(tm)
advanced protein expression technology.
cGMP manufacturing is sited in the north east of the UK for recombinant
protein biologics offering flexible capacity from 100L - 5000L for all stages of the product pipeline.
Avecia is supporting the bursary prize competition.
If you would like further information please contact:
Bridget Hall
Event and Bursary sponsor
GlaxoSmithKline (GSK) welcomes this opportunity to sponsor the Annual bioProcessUK Conference 2008. It provides us with an opportunity to highlight our commitment to biopharmaceuticals - a growth area for GSK. GSK is committed to establishing leadership in the discovery, development and delivery of biopharmaceutical medicines to target areas of high unmet medical need where conventional small-molecule therapies have proven inadequate. This commitment is exemplified in the formation of the Biopharmaceutical Centre of Excellence for Drug Discovery in 2004, the acquisition of Domantis in 2007 and the in-licensing of a number of late stage biopharmaceutical assets over the last 3 years. The result is a strong biopharmaceutical portfolio across a range of therapeutic areas including respiratory, oncology, inflammation, neurology and metabolic and spanning all development stages from early Discovery through to Filing. GSK has world-class research, development and manufacturing staff and facilities in Europe (including the UK) and the US to enable the progression of these biopharmaceutical products from discovery through development to the marketplace.
GSK's biopharmaceutical strategy is an integral part of achieving our mission to improve the quality of human life by enabling people to do more, feel better and live longer.
Glaxo Smith Kline are supporting the bursary prize competition.
If you would like further information please contact:
Carol Marshall
Event and Bursary sponsor
Invitrogen Corporation (NASDAQ:IVGN) provides products and services that support academic and government research institutions and pharmaceutical and biotech companies worldwide in their efforts to improve the human condition. The company provides essential life science technologies for disease research, drug discovery, and commercial bioproduction. Invitrogen's own research and development efforts are focused on breakthrough innovation in all major areas of biological discovery including functional genomics, proteomics, stem cells, cell therapy and cell biology -- placing Invitrogen's products in nearly every major laboratory in the world. Founded in 1987, Invitrogen is headquartered in Carlsbad, C alifornia, and conducts business in more than 70 countries around the world. The company employs approximately 4,700 scientists and other professionals and had revenues of approximately $1.3 billion in 2007.
Avecia is supporting the bursary prize competition.
If you would like further information please contact:
Vicky Smith
Event and Bursary sponsor
Novartis Vaccines is the world's fifth-largest vaccines business and is a global leader in the development and manufacture of influenza and meningococcal vaccines. Its portfolio of products also includes paediatric and travel vaccines and it has manufacturing and/or research facilities in Liverpool, UK, Siena and Rosia, Italy, Marburg in Germany with a global leadership centre in Cambridge, Massachusetts.
Novartis Vaccines are supporting the bursary prize competition.
If you would like further information please contact:
Fintan Weston
Event sponsor
Backed by the long-standing expertise of DifcoT and BBLT brand supplements and media, BD Biosciences - Advanced Bioprocessing's novel portfolio of hydrolysates, cell culture media supplements and services is the optimal choice for your mammalian cell culture and bacterial fermentation bioprocessing needs. As a strategic platform of BD Biosciences, Advanced Bioprocessing products are currently being used as critical components in the production of some of the most widely used drugs and vaccines on the global market today.
If you would like further information please contact:
Yann Pouliquen
Event sponsor
Eden Biodesign is one of the UK's leading biologics contract manufacturers and fully integrated biopharmaceutical development organisation. We operate a state of the art $70 million facility in Liverpool, UK that provides a full range of services for biopharmaceuticals: cell line/strain development and banking, process development, clinical trial cGMP manufacturing and analytical development for all significant product technologies - mammalian, microbial and viral to a worldwide client base.
If you would like further information please contact:
Johanne Tabern
Event sponsor
In 1897, Lonza was founded on the banks of the river Lonza in the Swiss Alps by adventurous entrepreneurs. Today, Lonza continues to embody that pioneering spirit as a leading partner to the pharmaceutical, healthcare, and life science industries.
For over 25 years, Lonza Custom Manufacturing has been helping emerging and large biotech and pharmaceutical companies improve and advance their products. Whether for clinical or commercial supply, Lonza's full set of development services, industry-leading manufacturing processes, and broad chemical and biotechnology platforms enable your products to reach their full potential.
Chemical synthesis, advanced intermediates, APIs, HAPIs, antibody drug conjugates, microbial fermentation, peptides, oligonucleotides, vaccines, plasmid DNA, mammalian cell culture, recombinant proteins, monoclonal antibodies, antibody fragments, cell therapy, research products and media services . Lonza has the know-how and experience to handle almost any pharmaceutical or biotechnology challenge, around the globe.
If you would like further information please contact:
Richard Alldread
Event sponsor
MedImmune, the worldwide biologics business for AstraZeneca, is dedicated to advancing science and medicine to help people live better lives. MedImmune's product pipeline is focused on infection, oncology, respiratory disease and inflammation, cardiovascular/gastrointestinal disease and neuroscience. The company's headquarters is located in Gaithersburg, Maryland. UK locations include a research center in Cambridge and vaccine manufacturing operations in Speke.
If you would like further information please contact:
Sidoney Atsé
Event sponsor
Smith & Nephew Technical Services Group is a new Contract Research Organisation which started up in January 2006 making its World Class analytical facilities available on an equal basis to external customers as well as internal clients. With particular expertise in Bioanalytical Services, we provide access to internationally recognised experts and state of the art facilities coupled with blue-chip industry standard project management and quality assurance to accelerate our customers' R&D programmes.
If you would like further information please contact:
Tony Harrison
Event sponsor
Xenova Biomanufacturing is a contract manufacturing organisation providing biologics development and manufacturing to the biopharmaceutical industry. Xenova, a leader in the biotechnology sector for many years, has built up an impressive expertise in bringing vaccines, therapeutic proteins and gene-therapy vectors from research through process development into manufacture for Phase 1 to Phase 3 clinical trials. This expertise, and the facilities we have developed, are offered commercially. Our services are based on our thorough understanding of the issues that small companies and project teams face when taking a product through development into the clinic. Xenova's manufacturing facilities are composed of independent GMP compliant suites for protein and live virus production. All facilities are MHRA authorised and in compliance with EU Clinical Trials Directive.
If you would like further information please contact:
Jim Mills
